Last updated: 11/07/2018 12:22:28
Survey of Antibiotic Resistance (SOAR) 2014-216 : Antibacterial resistance among Streptococcus pneumoniae , and Haemophilus influenza in Europe, Africa, Asia-Pacific LATAM and CIS
GSK study ID
201818
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: Survey of Antibiotic Resistance (SOAR) 2014-216 : Antibacterial resistance among Streptococcus pneumoniae , and Haemophilus influenza in Europe, Africa, Asia-Pacific LATAM and CIS
Trial description: Survey of Antibiotic Resistance (SOAR) 2014-216 : Antibacterial resistance among Streptococcus pneumoniae , and Haemophilus influenza in Europe, Africa, Asia-Pacific LATAM and CIS
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
D. Torumkuney, N. Mayanskiy, M. Edelstein, S. Sidorenko, R. Kozhevin, I. Morrissey. Results from the Survey of Antibiotic Resistance (SOAR) 2014-2016 in Russia. J Antimicrob Chemother. 2018;73(5):v14-v21.
Medical condition
Infections, Respiratory Tract
Product
amoxicillin, amoxicillin/clavulanic acid, azithromycin, cefuroxime axetil, clavulanic acid
Collaborators
Not applicable
Study date(s)
September 2015 to March 2017
Type
Not applicable
Phase
4
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
No study documents available.
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2017-30-03
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website